论文部分内容阅读
目的 观察粒 巨噬细胞集落刺激因子 (rHuGM CSF)联合黄芪注射液治疗慢性再生障碍性贫血的临床疗效。方法 所选再生障碍性贫血患者 2 5例均经系统治疗 ,其中rHuGM CSF治疗再生障碍性贫血 11例 ,rHuGM CSF联合黄芪治疗 14例 ,检查患者治疗前后外周血象及T细胞亚群变化。结果 对照组与治疗组治疗前后组内相比白细胞及血小板明显提高 (P <0 0 5 ) ,外周血CD+ 3 、CD+ 4 亚群细胞升高 ,CD+ 8亚群细胞降低 ,但差异均无显著意义 (P >0 0 5 ) ;白细胞及血小板升高后稳定时间相比 ,后者明显长于前者 (P <0 0 5 ) ;T细胞亚群治疗前后差值治疗组与对照组相比差异有显著意义 (P <0 0 5 )。结论 黄芪注射液能够明显提高rHuGM CSF治疗慢性再生障碍性贫血的临床疗效
Objective To observe the clinical efficacy of rHuGM CSF and astragalus injection in the treatment of chronic aplastic anemia. Methods Twenty-five patients with aplastic anemia were treated by systemic therapy. Among them, 11 were treated with rHuGM CSF and 14 were treated with rHuGM CSF combined with astragalus. The changes of peripheral blood and T cell subsets were examined before and after treatment. Results The levels of leukocytes and platelets in the control group and the treatment group before and after treatment were significantly increased (P <0.05). The numbers of CD + 3 and CD + 4 subpopulations were increased and the CD + 8 subpopulations were decreased in the control and treatment groups, but no significant difference was found (P 0.05). Compared with the control group, the difference of the stabilization time of white blood cells and platelets after treatment was significantly longer than the former (P <0.05) Significant (P <0 05). Conclusion Astragalus injection can significantly improve the clinical efficacy of rHuGM CSF in the treatment of chronic aplastic anemia